The Foundation board is comprised of medical professionals with experience in myocarditis and lay persons who have been touched by the disease.

Dr. Leslie T. Cooper, MD – Co-Founder, Chair, Enterprise Dept. of Cardiovascular Medicine for all of Mayo Clinic.

Dr. Jack Price, MD, Professor of Pediatrics at Baylor College of Medicine, Cardiologist at Texas Children’s Hospital.

Dr. Bettina Heidecker, MD, Head of Heart Failure and Cardiomyopathies Charite Hospital, Berlin, Germany.

Candace Moose – Co-Founder, Giant Cell Myocarditis Survivor and Transplant Recipient.

Joseph Rumore, Viral Myocarditis Survivor and former Managing Director of a national insurance company.

Louis Romano, Owner of Home Well Care.

Francine Andrea, Vice President for Enrollment Management, Student Affairs and Chief Compliance Officer for Felician University.

Joel Aranson, Founder and Chairman of National Sporting Good Corporation and father of a Giant Cell Myocarditis victim.

Giustina Schiano, Mother of a Viral Myocarditis victim and Family Advocate for the Myocarditis Foundation.

Michael A. Linn, Sales Leader for the Instruments Division of the Stryker Corporation.

Stephanie Kennan, Senior Vice President of Federal Affairs at McGuire Woods Consulting.

Gary Kubera, Former Chemical Industry Executive and CEO.

Dr. Akira Matsumori, MD – Professor of Medicine Dept. of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Bruce M. McManus, MD, PhD – Professor Emeritus, UBC Centre for Heart Lung Innovation Founding CEO, PROOF Centre of Excellence Vancouver, British Columbia, Canada.

Dennis M. McNamara, MD – Professor of Medicine, Director Center for Heart Failure Research University of Pittsburgh Medical Center.

DeLisa Fairweather, PhD, FAHA, Director of Translational Research and Associate Professor of Medicine in the Dept. of Cardiovascular Medicine at Mayo Clinic in Jacksonville, Florida.

Wilson Tang, MD – Professor of Medicine at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Practicing heart failure and transplant cardiologist at the Cleveland Clinic specializing in Cardiomyopathies and Myocarditis.

Enrico Ammirati, MD, PhD – Asst. Professor at the School of Medicine at the Vita-Salute San Raffaele University in Milan, Italy. Clinical Cardiologist who subspecializes in heart failure and myocarditis at the DeGasparis Cardio Center and Transplant Center at the Niguarda Hospital, Milan, Italy.

Justin Godown, MD – Asst. Professor at Monroe Carell, Jr., Children’s Hospital at Vanderbilt, Medical Director of Pediatric Cardiomyopathy and Cardio Oncology and practicing Pediatric Cardiologist.

The Myocarditis Foundation (MF) seeks to increase awareness and hasten progress in understanding myocarditis by awarding grants to help guarantee that new and innovative research avenues are thoroughly funded and explored. Please donate now.

The MF is a private, non-profit organization that exists to educate physicians and the public about this rare disease and support the patients and their families who have been affected by the disease. All of the money donated to MF will go directly to programs and services.

For more information:
info@myocarditisfoundation.org

Internet Resources
Children’s Cardiomyopathy Foundation: www.childrenscardiomyopathy.org
Parent Heart Watch: www.parentheartwatch.org
Compassionate Friends: www.compassionatefriends.org
American Heart Association: www.americanheart.org
MyocarditisFoundation.org

Website Resources
Please call the MF at 281-713-2962, or email Gen at gen@myocarditisfoundation.org. You can also go onto the Inspire.com website and go into the Myocarditis Community Page to speak with others who have been affected by myocarditis.
**DEFINITION: What is Myocarditis?**

Myocarditis is a rare, sometimes fatal disease characterized by inflammation of the heart muscle. The disease can affect the muscle cells of the heart (myocytes), the heart valves and blood vessels, and the specialized electrical conduction pathways within the heart.

Most patients recover completely from acute or sudden myocarditis. In newborns, myocarditis can be severe due to an immature immune system. Other organ systems may also be affected in this group of patients. Myocarditis is an important cause of sudden death in young athletes.

When the muscle cells of the heart weaken from myocarditis, the heart chambers may enlarge. This form of heart disease is called dilated cardiomyopathy. Children with dilated cardiomyopathy may develop symptoms of heart failure, sometimes necessitating a heart transplant. Heart failure resulting from myocarditis-induced dilated cardiomyopathy is a significant cause of disability and death in children.

**DEFINITION: What is Pediatric Myocarditis?**

Myocarditis is inflammation of the heart muscle. When myocarditis affects children younger than 18 years of age, it is called pediatric myocarditis.

In newborns the disease can be especially severe because of an underdeveloped immune system. Myocarditis can present in young athletes as sudden death. The incidence of dilated cardiomyopathy in children ranges from 0.57 to 0.76 cases per 100,000 children. Myocarditis is associated with dilated cardiomyopathy in 27% to 46% of cases. Dilated cardiomyopathy is the primary indication for childhood heart transplantation. Therefore, heart failure resulting from myocarditis-induced dilated cardiomyopathy is a significant cause of disability and death in children as well as adults.

**ETOLOGY: What Causes Pediatric Myocarditis?**

Myocarditis may be caused by infections in the heart, autoimmune disorders, hypersensitivity reactions to drugs and toxin exposure. Viruses are the most common cause of myocarditis in children. Many other viruses have also been implicated in children including Adenovirus, Parvovirus B19, hepatitis B and C viruses and HIV. The heart can be damaged by the virus itself or by the body’s immune defense against the virus. Drugs including some antibiotics, antipsychotics and anticonvulsants may rarely cause hypersensitivity reactions resulting in inflammation of the heart. Scorpion bites have been associated with myocarditis primarily in India. Autoimmune disorders associated with myocarditis include: systemic lupus erythematosus, celiac disease, and sarcoidosis. Finally, Giant Cell Myocarditis is a rare but serious cause of acute dilated cardiomyopathy and heart failure carrying a high risk of death unless heart transplantation is performed.

**DIAGNOSIS: How is Pediatric Myocarditis Detected?**

A physical examination may reveal signs of respiratory distress or decreased cardiac function. Clinical findings may include: rapid respiratory or heart rate, retraction of the respiratory muscles, nasal flaring, distended neck veins, weakened pulse, irregular heart rhythm, cool extremities, enlarged liver, low blood pressure. Some patients may develop a change in their mental status, becoming confused, disoriented or non-interactive. Blood tests for cardiac injury may help establish a diagnosis of myocarditis. Blood levels of troponin I and B-type natriuretic peptide (BNP or NT-pro BNP) are frequently elevated. A chest x-ray may reveal lung congestion or an enlarged heart. The electrocardiogram (ECG) is abnormal in about half of cases and may show decreased electrical voltages or an irregular heart rhythm. An echocardiogram (Echo) is usually nonspecific but may reveal decreased left and/or right ventricular pump function. Magnetic resonance imaging (MRI) may detect inflammation of the heart muscle and give additional information about the size and function of the heart.

Once a diagnosis of myocarditis is suspected and other common causes of cardiomyopathy have been excluded, a cardiologist may perform a cardiac catheterization to retrieve tissue samples from the inner lining of the heart. This is called an endomyocardial biopsy. The biopsy is the gold standard for diagnosis of myocarditis but its use is limited by risks associated with the procedure. Tissue obtained by this procedure may also yield clues as to the identity of the causative agent. The Pediatric Cardiomyopathy Registry, a study funded by the National Heart, Lung and Blood Institute, has reported that only one-third of children have a defined cause of their cardiomyopathy.

**SIGNS AND SYMPTOMS: When to Suspect Pediatric Myocarditis**

Clinical manifestations of acute viral myocarditis are usually nonspecific and highly variable. They range from mild flu-like symptoms to sudden death. Many infants and children with myocarditis present with fulminant features such as rapid and labored breathing, wheezing, grunting, low blood pressure, cool extremities and decreased urine output. Older children may complain of fatigue, fever, vomiting and muscle aches a few days before developing more severe symptoms such as shortness of breath and exercise intolerance. More advanced symptoms include rapid heart rate, erratic and weakened pulse, pale color, sweating and dizziness.

**THERAPY: What are the Treatment Options for Myocarditis?**

The primary treatment of myocarditis is supportive care based on guidelines and recommendations published by major cardiovascular organizations in North America and Europe. There are specific guidelines for the management of heart failure in children and standards of care for heart transplantation and pediatric cardiomyopathies. Children with a new diagnosis of myocarditis usually require hospitalization for treatment of heart failure and arrhythmias. Administration of intravenous cardiac medications or insertion of a temporary pacemaker may be necessary. In severe cases, extracorporeal membrane oxygenation (ECMO) or a ventricular assist device (VAD) that bypasses the native heart may be required in the acute phase to allow the heart to recover or to serve as a bridge to transplantation. Immmoglobulin (IVIG) or corticosteroids have been used in some acute cases to inhibit the immune response. Following the acute phase, surviving patients may recover completely or have long-term deficits in cardiac function. Some patients may develop a slow and progressive course of dilated cardiomyopathy with diminishing cardiac function and heart failure symptoms. In severe cases cardiac transplantation may offer the best chance for long-term survival.

**EXPECTED OUTCOMES: What is the Prognosis for Myocarditis Patients?**

Although many children recover from myocarditis with no serious consequences, severe forms of myocarditis are associated with significant morbidity and mortality worldwide. Children with fulminant myocarditis are more likely to achieve a complete recovery if they survive the acute phase. Children who develop cardiomyopathy and progress to end-stage heart failure, despite optimal medical therapy, may be candidates for cardiac transplantation. Transplant-free survival rates are highly variable, ranging from 40% to 75% over 5 years. A recent study demonstrated improved 1 and 5 year survival rates of 90% and 83%, respectively. Predictors of outcome in children with dilated cardiomyopathy include severity of symptoms, the presence or absence of arrhythmias and the rate of clinical improvement. After therapy, post-transplantation survival rates are 80% at 1 year and 70% at 5 years.